Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Tetraphase Pharmaceuticals revenue
Tetraphase Pharmaceuticals's revenue is $7.4 million.
What is Tetraphase Pharmaceuticals's revenue?
- Tetraphase Pharmaceuticals's revenue growth from 2012 to 2019 is -2.95%.
- Tetraphase Pharmaceuticals has 67 employees, and the revenue per employee ratio is $110,089.
- Tetraphase Pharmaceuticals's peak quarterly revenue was $11.6M in 2018(q2).
- Tetraphase Pharmaceuticals peak revenue was $18.9M in 2018.
- Tetraphase Pharmaceuticals annual revenue for 2018 was 18.9M, 95.57% growth from 2017.
- Tetraphase Pharmaceuticals annual revenue for 2019 was 7.4M, -60.98% growth from 2018.
On this page
Zippi applies for you, and finds you a job.
Tetraphase Pharmaceuticals historical revenue
Tetraphase Pharmaceuticals's peak revenue was $18.9M in 2018. The peak quarterly revenue was $11.6M in 2018(q2).
Tetraphase Pharmaceuticals's revenue increased from $7.6m in 2012 to $7.4M currently. That's a -2.95% change in annual revenue.
Tetraphase Pharmaceuticals annual revenue
Tetraphase Pharmaceuticals annual revenue over time
| Fiscal year / year | Tetraphase Pharmaceuticals revenue |
|---|---|
| 2012 | $7.6M |
| 2013 | $10.5M |
| 2014 | $9.1M |
| 2015 | $11.7M |
| 2016 | $5.1M |
| 2017 | $9.7M |
| 2018 | $18.9M |
| 2019 | $7.4M |
Rate Tetraphase Pharmaceuticals' financial transparency
Tetraphase Pharmaceuticals annual growth
Tetraphase Pharmaceuticals saw the greatest revenue growth in 2018, when revenue increased by 95.57%.
Tetraphase Pharmaceuticals had the lowest revenue growth in 2019, when revenue changed by -60.98%.
Tetraphase Pharmaceuticals annual growth rate over time
| Year | Tetraphase Pharmaceuticals growth |
|---|---|
| 2013 | 38%↑ |
| 2014 | -13%↓ |
| 2015 | 28%↑ |
| 2016 | -56%↓ |
| 2017 | 88%↑ |
| 2018 | 96%↑ |
| 2019 | -61%↓ |
Tetraphase Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Tetraphase Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | - | - | - | $3.2M |
| 2013 | $2.7M | $3.7M | $2.2M | $1.9M |
| 2014 | $2.5M | $1.3M | $2.3M | $3.1M |
| 2015 | $3.0M | $3.3M | $2.9M | $2.5M |
| 2016 | $2.0M | $1.2M | $850,000 | $1.1M |
| 2017 | $1.5M | $1.6M | $4.1M | $2.5M |
| 2018 | $1.9M | $11.6M | $1.2M | $4.3M |
| 2019 | $1.3M | $1.1M | $3.3M | $1.7M |
| 2020 | $1.8M | - | - | - |
Tetraphase Pharmaceuticals jobs nearby
Do you work at Tetraphase Pharmaceuticals?
Did Tetraphase Pharmaceuticals meet its revenue projections?
Tetraphase Pharmaceuticals financial information
| CEO | Larry Edwards |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 67 |
| Date Founded | 2006 |
| Headquarters | Watertown Town, Massachusetts |
| Number of Locations | 2 |
| Revenue | $7.4M |
| Net Income | -$70,085,000 |
| Gross Proft | $4.3M (2019) |
| PE Ratio | -0.80 |
| Market Capitalization | $56.3M |
| Total Assets | $36,385,000 |
| Ticker | TTPH |
Tetraphase Pharmaceuticals jobs you might like
Tetraphase Pharmaceuticals financing
Tetraphase Pharmaceuticals received early financing of $10.0M on 2006-11-01.
| Series | Round size | Date |
|---|---|---|
| Series A | $10M | 11/2006 |
| Series A | $15M | 08/2008 |
| Series B | $25M | 09/2009 |
| Series C | $45M | 06/2010 |
| Grant | $4M | 04/2017 |
Tetraphase Pharmaceuticals investors
| Investors | Security type |
|---|---|
| MEDIPHASE VENTURE PARTNERS | Series A |
| Skyline Ventures | Series A |
| F Prime Capital | Series A |
| CMEA Ventures | Series A |
| Flagship Pioneering Inc | Series A |
| MEDIPHASE VENTURE PARTNERS | Series A |
| Fidelity Ventures | Series A |
| Skyline Ventures | Series A |
| CMEA Capital | Series A |
| Flagship Pioneering Inc | Series A |
| MEDIPHASE VENTURE PARTNERS | Series B |
| Skyline Ventures | Series B |
| F Prime Capital | Series B |
| CMEA Ventures | Series B |
| Flagship Pioneering Inc | Series B |
| Excel Venture Management | Series C |
| MEDIPHASE VENTURE PARTNERS | Series C |
| Skyline Ventures | Series C |
| CMEA Capital | Series C |
| F Prime Capital | Series C |
| Flagship Pioneering Inc | Series C |
| CARB X | Grant |
Tetraphase Pharmaceuticals competitors
Tetraphase Pharmaceuticals's top competitor, Alnylam Pharmaceuticals, earned an annual revenue of $2.2B.
Tetraphase Pharmaceuticals's smallest competitor is Cylene Pharmaceuticals with revenue of $284.9K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | $81,014 | $2.2B | 1,323 | - |
| Forma Therapeutics | $79,424 | $100.6M | 103 | - |
| Verastem Oncology | $101,471 | $10.0M | 150 | 7 |
| Momenta Pharmaceuticals | $76,894 | $30.1M | 131 | - |
| Cylene Pharmaceuticals | $69,047 | $284.9K | 3 | - |
| Redox Pharmaceutical | $65,095 | - | 6 | - |
| Constellation Pharmaceuticals | $65,259 | $4.7M | 82 | - |
| Dabur Research Foundation | $79,169 | $40.0M | 1,000 | - |
Tetraphase Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Tetraphase Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Tetraphase Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Tetraphase Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Tetraphase Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Tetraphase Pharmaceuticals. The data presented on this page does not represent the view of Tetraphase Pharmaceuticals and its employees or that of Zippia.
Tetraphase Pharmaceuticals may also be known as or be related to TETRAPHASE PHARMACEUTICALS INC, Tetraphase Pharmaceuticals, Tetraphase Pharmaceuticals Inc and Tetraphase Pharmaceuticals, Inc.